Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa | Dermatology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis SuppurativaThe SHARPS Randomized Clinical Trial

Educational objective To determine the efficacy and safety of adalimumab in conjunction with surgery in adults with moderate to severe hidradenitis suppurativa.
1 Credit CME
Key Points

Question  What is the efficacy and safety of adalimumab in conjunction with surgery in adult patients with moderate to severe hidradenitis suppurativa (HS)?

Findings  In this randomized clinical trial of 206 patients, significantly more patients receiving adalimumab achieved HS clinical response across all body regions vs placebo at week 12 and improvements in quality of life.

Meaning  Adalimumab was efficacious in patients with HS, with no need to interrupt treatment prior to surgery; these findings may help to guide medical treatment decisions for patients with HS who are candidates for surgery.

Abstract

Importance  Surgery is a mainstay in the management of hidradenitis suppurativa (HS). Adalimumab is the first drug approved for HS.

Objective  To investigate the efficacy and safety of adalimumab in combination with wide-excision surgery followed by secondary intention healing.

Design, Setting, and Participants  The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial was a phase 4, randomized, double-blind, placebo-controlled study of adalimumab in conjunction with surgery. Patients were enrolled in 45 sites across 20 countries from July 18, 2016, to February 2, 2019, with the last patient visit on October 16, 2019. Eligible patients (aged 18-65 years) had moderate to severe HS that required radical surgery in an axillary or inguinal region and had 2 other anatomical regions affected, with 1 or more regions at Hurley stage II or III. Analysis was conducted in November 2019.

Interventions  Patients were randomized 1:1 to receive continuous adalimumab, 40 mg, or placebo during presurgery (12 weeks), perioperative (2 weeks), and postoperative (10 weeks) periods.

Main Outcomes and Measures  The primary end point was the proportion of patients achieving HS clinical response across all body regions at week 12.

Results  Overall, 103 patients were randomized to adalimumab and 103 to matching placebo. Among all patients, 51% (n = 106) were women, 94% (n = 193) were White, and the mean (SD) age was 37.6 (11.3) years. At week 12, significantly more patients receiving adalimumab (49 of 103 [48%]) vs placebo (35 of 103 [34%]; P = .049) achieved HS clinical response across all body regions (treatment difference, 14% [95% CI, 0%-27%]). Treatment-emergent adverse events were reported in 74 of 103 patients (72%) and 69 of 103 patients (67%) in the adalimumab and placebo groups, respectively. No increased risk of postoperative wound infection, complication, or hemorrhage was observed with adalimumab vs placebo. Two deaths occurred in the adalimumab group; neither was considered as having a reasonable possibility of relationship to study drug.

Conclusions and Relevance  Adalimumab was efficacious in conjunction with wide-excision surgery followed by secondary intention healing, with no need to interrupt treatment prior to surgery. These data support further investigation of adalimumab as an adjuvant therapy to surgery in patients with moderate to severe HS.

Trial Registration  ClinicalTrials.gov Identifier: NCT02808975

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Falk G. Bechara, MD, Department of Dermatology, Venereology, and Allergology, St Josef Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany (f.bechara@klinikum-bochum.de).

Accepted for Publication: May 25, 2021.

Published Online: August 18, 2021. doi:10.1001/jamasurg.2021.3655

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2021 Bechara FG et al. JAMA Surgery.

Author Contributions: Dr Bechara had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Bechara, Podda, Prens, Horváth, Alavi, Geng, Jean, Jemec, Zouboulis.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Bechara, Horváth, Geng, Jean.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Geng.

Administrative, technical, or material support: Podda, Prens, Giamarellos-Bourboulis, Alavi, Jemec.

Supervision: Bechara, Podda, Prens, Horváth, Giamarellos-Bourboulis, Alavi, Kirby, Jean, Jemec, Zouboulis.

Conflict of Interest Disclosures: Dr Bechara received honoraria from AbbVie, Novartis, and Janssen for advisory board and speaker services, and his department received grants from AbbVie, Novartis, UCB, InflaRx, Incyte, and Janssen for his participation as an investigator. Dr Podda reported personal fees from AbbVie and grants from AbbVie paid to Klinikum Darmstadt during the conduct of the study; personal fees and grants paid to Klinikum Darmstadt from Beiersdorf, Bristol Myers Squibb, CSL Behring, Galderma, Janssen-Cilag, Leo Pharma, Novartis, MSD, USB, Boehringer Ingelheim, Eli Lilly and Company, and InflaRx outside the submitted work. Dr Prens received honoraria from AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen-Cilag, Galderma, InflaRx, Novartis, UCB, Regeneron, and Pfizer for speaker and advisory board services and received investigator-initiated grants (paid to the Erasmus MC) from AbbVie, Celgene, Janssen-Cilag, and UCB. Dr Horváth reported grants from Janssen-Cilag, AbbVie, Novartis, UCB Pharma, and Leo Pharma paid to their institution during the conduct of the study; grants from Solenne BV, Celgene, Akari Therapeutics, Philips, Roche, Regeneron, and Sanofi paid to their institution outside the submitted work; and personal fees from Janssen-Cilag, AbbVie, Novartis Pharma, UCB Pharma, Leo Pharma, Solenne BV, Celgene, Akari Therapeutics, Philips, Roche, Regeneron, and Sanofi paid to their institution. Dr Giamarellos-Bourboulis reported grants from AbbVie for the SHARPS study to the National and Kapodistrian University of Athens during the conduct of the study; grants from Abbott, InflaRx, XBiotech, Astellas Pharma, Axis Shield, Horizon 2020 ImmunoSep, bioMérieux, FrameWork 7 HemoSpec, and Horizon 2020 Marie Curie ITN European Sepsis Academy; personal fees from Abbott, XBiotech, Angelini Pharma, Pfizer, and ThermoFisher outside the submitted work; and honoraria from MSD. Dr Alavi reported grants from AbbVie during the conduct of the study; personal fees from Novartis, Janssen, Kymera Therapeutics, and AbbVie outside the submitted work; and has acted as a consultant, advisor, and/or received research funding from Asana, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Galderma, Genentech, Glenmark, Incyte, InflaRx, Leo Pharma, Novartis, Regeneron, UCB, and Valeant. Dr Szepietowski is an advisory board member of AbbVie, Leo Pharma, Novartis, Pierre Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, and Trevi; principal investigator for AbbVie, Novartis, Menlo Therapeutics, Trevi, Janssen, Merck, Regeneron, Amgen, Boehringer Ingelheim, Galapagos, Galderma, InflaRx, Kymab, Pfizer, UCB, Helm, and Incyte; speaker for AbbVie, Novartis, Janssen, Eli Lilly, Sanofi Genzyme, Sun Pharma, and Berlin-Chemie Menarini; and reported personal fees from AbbVie during the conduct of the study and outside the submitted work. Dr Kirby reported personal fees from AbbVie, ChemoCentryx, Incyte, Novartis, Janssen, and UCB Pharma outside the submitted work. Dr Geng reported owns AbbVie stock as an employee. Dr Jean reported being a former employee of AbbVie and owns stock or stock options. Dr Jemec reported grants from AbbVie, InflaRx, Novartis, Janssen-Cilag, CSL Behring, Afyx, Regeneron, and Leo Pharma; personal fees from UCB Pharma, Incyte, and ChemoCentryx during the conduct of the study; personal fees from Coloplast, Novartis, and Leo Pharma outside the submitted work; a patent for a probiotic pending; is editor in chief of Dermatology; advisor at Miiskin and Henlez; honoraria from Kymera and VielaBio. Dr Zouboulis reported grants from AbbVie paid to the Dessau Medical Center during the conduct of the study; grants from AbbVie paid to the Dessau Medical Center outside the submitted work; personal fees from AbbVie outside the submitted work; personal consultation/lecture/advisory board honoraria from Almirall, Bayer, Celgene, Galderma, GlaxoSmithKline/Stiefel, Idorsia, Incyte, InflaRx, Janssen, Novartis, Pierre Fabre, PPM Pharma, Regeneron, Sobi, UCB; and fees paid to the Dessau Medical Center for participation at clinical studies from Advanced Oxygen Therapy Inc, AstraZeneca, Galderma, InflaRx, NAOS-Bioderma, Novartis, PPM Pharma, Relaxera, and UCB Pharma.

Funding/Support: AbbVie funded this study.

Role of the Funder/Sponsor: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.

Meeting Presentation: Findings from the SHARPS study were previously presented at the 9th Conference of the European Hidradenitis Suppurativa Foundation; February 6, 2020; Athens, Greece.

Data Sharing Statement: See Supplement 3.

Additional Contributions: AbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical study. Medical writing support was provided by Madhura Mehta, PhD, and Janet Matsuura, PhD, of ICON and was funded by AbbVie.

References
1.
Zouboulis  CC , Desai  N , Emtestam  L ,  et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.   J Eur Acad Dermatol Venereol. 2015;29(4):619-644. doi:10.1111/jdv.12966PubMedGoogle ScholarCrossref
2.
Ellis  LZ .  Hidradenitis suppurativa: surgical and other management techniques.   Dermatol Surg. 2012;38(4):517-536. doi:10.1111/j.1524-4725.2011.02186.xPubMedGoogle ScholarCrossref
3.
Lee  EY , Alhusayen  R , Lansang  P , Shear  N , Yeung  J .  What is hidradenitis suppurativa?   Can Fam Physician. 2017;63(2):114-120.PubMedGoogle Scholar
4.
Orenstein  LAV , Nguyen  TV , Damiani  G , Sayed  C , Jemec  GBE , Hamzavi  I .  Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice.   Dermatology. 2020;236(5):393-412. doi:10.1159/000507323PubMedGoogle ScholarCrossref
5.
Alharbi  Z , Kauczok  J , Pallua  N .  A review of wide surgical excision of hidradenitis suppurativa.   BMC Dermatol. 2012;12:9. doi:10.1186/1471-5945-12-9PubMedGoogle ScholarCrossref
6.
Alikhan  A , Sayed  C , Alavi  A ,  et al.  North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management.   J Am Acad Dermatol. 2019;81(1):76-90. doi:10.1016/j.jaad.2019.02.067PubMedGoogle ScholarCrossref
7.
Shanmugam  VK , Zaman  NM , McNish  S , Hant  FN .  Review of current immunologic therapies for hidradenitis suppurativa.   Int J Rheumatol. 2017;2017:8018192. doi:10.1155/2017/8018192PubMedGoogle Scholar
8.
Humira. Accessed June 30, 2021. https://www.humira.com/
9.
Kimball  AB , Okun  MM , Williams  DA ,  et al.  Two phase 3 trials of adalimumab for hidradenitis suppurativa.   N Engl J Med. 2016;375(5):422-434. doi:10.1056/NEJMoa1504370PubMedGoogle ScholarCrossref
10.
Zouboulis  CC , Okun  MM , Prens  EP ,  et al.  Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.   J Am Acad Dermatol. 2019;80(1):60-69.e2. doi:10.1016/j.jaad.2018.05.040Google ScholarCrossref
11.
Kimball  AB , Kerdel  F , Adams  D ,  et al.  Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.   Ann Intern Med. 2012;157(12):846-855. doi:10.7326/0003-4819-157-12-201212180-00004PubMedGoogle ScholarCrossref
12.
Miller  I , Lynggaard  CD , Lophaven  S , Zachariae  C , Dufour  DN , Jemec  GB .  A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.   Br J Dermatol. 2011;165(2):391-398. doi:10.1111/j.1365-2133.2011.10339.xPubMedGoogle ScholarCrossref
13.
Shanmugam  VK , Mulani  S , McNish  S , Harris  S , Buescher  T , Amdur  R .  Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.   Int J Dermatol. 2018;57(1):62-69. doi:10.1111/ijd.13798PubMedGoogle ScholarCrossref
14.
DeFazio  MV , Economides  JM , King  KS ,  et al.  Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa.   Ann Plast Surg. 2016;77(2):217-222. doi:10.1097/SAP.0000000000000584PubMedGoogle ScholarCrossref
15.
Prens  LM , Huizinga  J , Janse  IC , Horváth  B .  Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.   J Eur Acad Dermatol Venereol. 2019;33(10):1941-1946. doi:10.1111/jdv.15706PubMedGoogle ScholarCrossref
16.
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.   JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053Google ScholarCrossref
17.
Kimball  AB , Sundaram  M , Banderas  B , Foley  C , Shields  AL .  Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa.   J Dermatolog Treat. 2018;29(2):152-164. doi:10.1080/09546634.2017.1341614PubMedGoogle ScholarCrossref
18.
Alikhan  A , Sayed  C , Alavi  A ,  et al.  North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management.   J Am Acad Dermatol. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068PubMedGoogle ScholarCrossref
19.
Zouboulis  CC , Bechara  FG , Dickinson-Blok  JL ,  et al.  Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization—systematic review and recommendations from the HS ALLIANCE working group.   J Eur Acad Dermatol Venereol. 2019;33(1):19-31. doi:10.1111/jdv.15233PubMedGoogle ScholarCrossref
20.
Gulliver  W , Zouboulis  CC , Prens  E , Jemec  GB , Tzellos  T .  Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.   Rev Endocr Metab Disord. 2016;17(3):343-351. doi:10.1007/s11154-016-9328-5PubMedGoogle ScholarCrossref
21.
Bechara  FG , Horvath  B , Jemec  GBE ,  et al.  Adalimumab in conjunction with surgery in patients with moderate to severe hidradenitis suppurativa: baseline characteristics from a phase 4, double-blind, randomized, placebo-controlled study.   Exp Dermatol. 2020;29(suppl 1):38Google Scholar
22.
Jemec  GBE , Okun  MM , Forman  SB ,  et al.  Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.   Br J Dermatol. 2019;181(5):967-975. doi:10.1111/bjd.17919PubMedGoogle ScholarCrossref
23.
Bechara  FG , Horvath  B , Jemec  GBE ,  et al.  Efficacy and safety results from the SHARPS Study: phase 4, randomized, controlled trial of adalimumab plus surgery in moderate-to-severe hidradenitis suppurativa.   Exp Dermatol. 2020;29(suppl 1):37.Google Scholar
24.
Amodeo  G , Bugada  D , Franchi  S ,  et al.  Immune function after major surgical interventions: the effect of postoperative pain treatment.   J Pain Res. 2018;11:1297-1305. doi:10.2147/JPR.S158230PubMedGoogle ScholarCrossref
25.
Dąbrowska  AM , Słotwiński  R .  The immune response to surgery and infection.   Cent Eur J Immunol. 2014;39(4):532-537. doi:10.5114/ceji.2014.47741PubMedGoogle Scholar
26.
von der Werth  JM , Williams  HC .  The natural history of hidradenitis suppurativa.   J Eur Acad Dermatol Venereol. 2000;14(5):389-392. doi:10.1046/j.1468-3083.2000.00087.xPubMedGoogle ScholarCrossref
27.
Ryan  C , Sobell  JM , Leonardi  CL ,  et al.  Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis.   Am J Clin Dermatol. 2018;19(3):437-447. doi:10.1007/s40257-017-0341-6PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close